Cel-Sci (NYSEAMERICAN:CVM) Stock Price Up 1% – Time to Buy?

Cel-Sci Corporation (NYSEAMERICAN:CVM)’s share price rose 1% during mid-day trading on Tuesday . The company traded as high as $1.0450 and last traded at $1.02. 189,884 shares were traded during trading, a decline of 43% from the average session volume of 335,736 shares. The stock had previously closed at $1.01.

Cel-Sci Trading Up 1.0%

The stock’s fifty day simple moving average is $2.02 and its 200-day simple moving average is $3.83. The company has a debt-to-equity ratio of 0.64, a current ratio of 0.60 and a quick ratio of 0.54. The firm has a market cap of $17.83 million, a PE ratio of -0.10 and a beta of 0.54.

Cel-Sci (NYSEAMERICAN:CVM) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.67) earnings per share for the quarter.

Institutional Trading of Cel-Sci

Several large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE increased its holdings in shares of Cel-Sci by 2,188.2% in the second quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock valued at $94,000 after purchasing an additional 39,190 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Cel-Sci by 59.7% during the third quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock worth $2,692,000 after purchasing an additional 109,352 shares during the period. MAI Capital Management lifted its holdings in shares of Cel-Sci by 18.4% during the third quarter. MAI Capital Management now owns 76,861 shares of the company’s stock worth $707,000 after purchasing an additional 11,928 shares during the period. US Bancorp DE purchased a new stake in Cel-Sci in the third quarter valued at approximately $80,000. Finally, HighTower Advisors LLC purchased a new stake in Cel-Sci in the fourth quarter valued at approximately $53,000. Hedge funds and other institutional investors own 12.08% of the company’s stock.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.